WeLeader Biomedical Co

WeLeader Biomedical Co Dividend per Share

The Dividend per Share of WeLeader Biomedical Co (7713.TWO) as of Oct 25, 2026 is 3.37 TWD. In the previous year, Dividend per Share was 2.30 TWD — a change of 46.43% (higher).

Dividend per Share

3.37TWD

YoY

46.43%

Last updated:

Dividend per Share of WeLeader Biomedical Co is 2025 3.37 TWD. Dividend per Share of WeLeader Biomedical Co was 2024 2.30 TWD. It decreases by 46.43% higher compared to the previous year.

At today's price the dividend yield works out to roughly 4.67%. The payout ratio is around 73% of earnings.

The WeLeader Biomedical Co Dividend per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend per Share
Date
Dividend per Share
Jan 1, 2020
0.00 TWD
Jan 1, 2021
0.00 TWD
Jan 1, 2022
0.00 TWD
Jan 1, 2023
0.00 TWD
Jan 1, 2024
2.30 TWD
Jan 1, 2025
3.37 TWD
Jan 1, 2026 (e)
4.04 TWD
The WeLeader Biomedical Co Dividend per Share history
YEARDividend per ShareYoY
est4.04TWD+20.00%
3.37TWD+46.43%
2.30TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Dividend per Share of WeLeader Biomedical Co is 3.37 TWD in 2025.

Dividend per Share of WeLeader Biomedical Co changed from 2.30 TWD to 3.37 TWD, representing a 46.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend per Share WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Dividend per share is the total dividend payment divided by shares outstanding. It shows how much cash each share receives in dividends.

Dividend per Share's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend per Share's WeLeader Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co